dc.date.accessioned | 2020-09-16T17:26:30Z | |
dc.date.accessioned | 2022-09-23T18:32:37Z | |
dc.date.available | 2020-09-16T17:26:30Z | |
dc.date.available | 2022-09-23T18:32:37Z | |
dc.date.created | 2020-09-16T17:26:30Z | |
dc.identifier | 2405-8440 | |
dc.identifier | https://doi.org/10.1016/j.heliyon.2020.e04900 | |
dc.identifier | http://hdl.handle.net/20.500.12010/13334 | |
dc.identifier | https://doi.org/10.1016/j.heliyon.2020.e04900 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/3502856 | |
dc.description.abstract | The COVID-19 outbreak emerged in December 2019 and has rapidly become a global pandemic. A great deal of
effort has been made to find effective drugs against this disease. Chloroquine (CQ) and hydroxychloroquine
(HCQ) were widely adopted in treating COVID-19, but the results were contradictive. CQ/HCQ have been used to
prevent and treat malaria and are efficacious anti-inflammatory agents in rheumatoid arthritis and systemic lupus
erythematosus. These drugs have potential broad-spectrum antiviral properties, but the underlying mechanisms
are speculative. In this review, we re-evaluated the treatment outcomes and current hypothesis for the working
mechanisms of CQ/HCQ as COVID-19 therapy with a special focus on disruption of Ca2þ signaling. In so doing, we
attempt to show how the different hypotheses for CQ/HCQ action on coronavirus may interact and reinforce each
other. The potential toxicity is also noted due to its action on Ca2þ and hyperpolarization-activated cyclic
nucleotide-gated channels in cardiac myocytes and neuronal cells. We propose that intracellular calcium homeostasis is an alternative mechanism for CQ/HCQ pharmacology, which should be considered when evaluating
the risks and benefits of therapy in these patients and other perspective applications. | |
dc.language | eng | |
dc.publisher | Heliyon | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.rights | Abierto (Texto Completo) | |
dc.source | reponame:Expeditio Repositorio Institucional UJTL | |
dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | |
dc.subject | Chloroquine | |
dc.subject | Hydroxychloroquine | |
dc.subject | Calcium | |
dc.subject | HCN | |
dc.subject | SARS-CoV-2 | |
dc.subject | Cardiology | |
dc.subject | Pathology | |
dc.subject | Infectious disease | |
dc.subject | Neurology | |
dc.subject | Pharmacology | |
dc.subject | Immunology | |
dc.subject | Clinical toxicology | |
dc.subject | Toxicology | |
dc.subject | Eye-ear-nose-throat | |
dc.subject | Internal medicine | |
dc.title | Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects? | |